Telithromycin in Respiratory Tract Infections

This study has been completed.
Sponsor:
Information provided by:
Sanofi
ClinicalTrials.gov Identifier:
NCT00261105
First received: December 1, 2005
Last updated: September 24, 2009
Last verified: September 2009
  Purpose

Primary Objectives:

  • The primary objective of the study is to evaluate clinical efficacy i.e. to show that with respect to clinical cure rate, Ketek® (telithromycin) in the treatment of community acquired respiratory tract infections: community acquired pneumonia (CAP), acute bacterial exacerbation of chronic bronchitis (AECB) and acute sinusitis (AS), in outpatients.

Secondary Objectives:

The secondary objectives are to:

  • Further assess the efficacy of Ketek® (telithromycin) by considering the rate at which additional antibacterials were prescribed to treat the primary infection; the rate of hospitalisation due to a complication of the primary infection and assessment of bacteriological data, chest X-ray and sinus X-ray if available.
  • Evaluate safety of Ketek® (telithromycin) through Adverse Event (AE) and Serious Adverse Event (SAE) reporting

Condition Intervention Phase
Respiratory Tract Infections
Drug: telithromycin
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open, Multicenter, Non-comparative, Phase IV Trial of Efficacy and Safety of Ketek(Telithromycin) 800mg

Resource links provided by NLM:


Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Clinical Outcome (Global Assessment by the participating physicians) [ Time Frame: During the Study Conduct ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Rate at which additional antibacterials were prescribed to treat the primary infection [ Time Frame: During the study conduct ] [ Designated as safety issue: No ]
  • Rate of hospitalisation due to a complication of the primary infection [ Time Frame: During the study conduct ] [ Designated as safety issue: No ]
  • Assessment of chest X-ray and sinus X-ray if available. [ Time Frame: During the study conduct ] [ Designated as safety issue: No ]
  • Adverse Event (AE) and Serious Adverse Event (SAE) reported [ Time Frame: from the inform consent signed up to the end of the study ] [ Designated as safety issue: No ]

Study Start Date: February 2005
Study Completion Date: December 2005
Primary Completion Date: October 2005 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

General Conditions

  • Outpatients
  • Fulfillment of clinical diagnostic criteria for one of the following indications:

    • Mild to moderate Community Acquired Pneumonia (CAP)
    • Acute bacterial Exacerbation of Chronic Bronchitis (AECB)
    • Acute Sinusitis (AS)

For CAP

The Criteria to be fulfilled are:

  • New onset of at least two of the following:

    • Cough
    • Production of purulent sputum
    • Auscultatory findings compatible with pneumonia, e.g. rales, evidence of pulmonary consolidation
    • Dyspnea or tachypnea
    • Fever
    • Elevated total white blood cell count > 10 000/mm3 or >15% bands regardless of total count
  • Chest X-ray findings supporting a clinical diagnosis of bacterial pneumonia (e.g. new infiltrate)

For AECB

The Criteria to be fulfilled are:

  • Chronic bronchitis defined as cough and excessive sputum production for more than 2 consecutive years and on most days in a 3-month consecutive period.
  • Exacerbation defined by:

    • Increase in sputum purulence, or
    • Increase in sputum volume, or
    • Increase in dyspnea

For AS

The criteria to be fulfilled are:

At least two of the major or one major and two minor factors listed below, for more than one week and less than 4 weeks:

  • Major factors:

    • Facial pressure and/or pain
    • Facial congestion or fullness
    • Nasal obstruction
    • Nasal purulence or postnasal discharge
    • Hyposmia or anosmia
    • Fever
  • Minor factors:

    • Headache
    • Halitosis
    • Fatigue
    • Dental pain
    • Cough
    • Ear pain, pressure or fullness

Exclusion Criteria:

General Conditions

Subjects presenting with any of the following will not be included in the study:

  • Treatment required during the study with ergot alkaloid derivatives, pimozide, astemizole, terfenadine, cisapride, simvastatin, atorvastatin and lovastatin, and the oral use of the benzodiazepines midazolam, triazolam and alprazolam.
  • History of congenital or family history of long QT syndrome (if not excluded by ECG) or known acquired QT interval prolongation.
  • Known hypersensitivity to telithromycin or to macrolide antibiotics.
  • Hospital acquired infections (hospitalization for more than 72 hours within 7 days of study entry).
  • Pregnant or breast-feeding women. For the women of childbearing potential it is left to the investigators discretion to establish a lack of pregnancy, e.g. with contraceptive use, menstrual pattern, urinary pregnancy test.
  • Subjects with severely impaired renal function (creatinine clearance <30 ml/min).
  • Subjects that had received anti-bacterials for more than 24 hours within 7 days prior to enrollment in the study, unless the treatment has failed.
  • Subjects receiving medications, including other anti-microbials or anti-cancer drugs, that could interfere with the evaluation.
  • Microbiologically documented infection with a pathogen known prior to inclusion to be resistant to the study medications.
  • Infection, other than the primary infection for which the subject is being included in the study that requires use of other systemic anti-bacterial drug.
  • Splenectomised subjects.
  • Use of Ketek® (telithromycin) or participation in a study using Ketek® (telithromycin) in the previous 30 calendar days.
  • Subjects that have received any investigational drug within 4 weeks of enrollment in the study.
  • No subject will be allowed to enroll in this study more than once.

For CAP

Additional exclusion criteria are:

  • Severe pneumonia defined by any one of the following:

    • Judged as needing Intensive Care Unit admission.
    • Need of parenteral antibiotic treatment (if the attending physician wants to prescribe a parenteral treatment for adherence reasons or local prescription habits this is accepted, provided that the patient does not have a severe pneumonia).
    • Acute respiratory failure or requirement for mechanical ventilation.
    • Altered mental status resulting from the infective process.
    • Resting respiratory rate > 30 breaths/min.
    • Chest X-ray showing increase in opacity by > 50% within 48 hours of current evaluation.
  • Total white blood cell count < 4 000/mm3.
  • Aspiration pneumonia.
  • Pneumonia suspected to be non-bacterial (due to fungus or viral).
  • Subjects suffering from severe bronchiectasis (production of more than 125 mL of sputum/day), cystic fibrosis, active tuberculosis, pulmonary infarction or embolism, bronchial obstruction, lung cancer or lung metastasis, lung abscess, extra-pulmonary extension (like meningitis, septic arthritis, endocarditis).

For AECB

Additional exclusion criteria are:

  • Need of parenteral antibiotic treatment (if the attending physician wants to prescribe a parenteral treatment for adherence reasons or local prescription habits this is accepted, provided that the patient does not have a severe infection).
  • Acute respiratory failure (respiratory distress, hypercarbia, worsening hypoxemia) or requirement for mechanical ventilation.
  • Severe bronchiectasis, cystic fibrosis, active tuberculosis, pulmonary infarction or embolism, bronchial obstruction, lung cancer or lung metastasis, lung abscess.

For AS

Additional exclusion criteria are:

  • Need of immediate surgery for the treatment of AS.
  • Chronic sinusitis (symptoms lasting more than 4 weeks).
  • Recurrent sinusitis (4 or more episodes of sinusitis requiring antibiotic therapy in the previous 12 months).
  • Nosocomial acquired sinusitis.
  • Cystic fibrosis, immotile cilia syndrome.
  • Obstructive lesions in nasopharynx (e.g. polyps, tumor).
  • Use of nasal, nasogastric or nasotracheal catheters.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00261105

Sponsors and Collaborators
Sanofi
Investigators
Study Director: Won-Sik Lee, MD Sanofi
  More Information

No publications provided

Responsible Party: Medical Affairs Study Director, sanofi-aventis
ClinicalTrials.gov Identifier: NCT00261105     History of Changes
Other Study ID Numbers: HMR3647A_4026
Study First Received: December 1, 2005
Last Updated: September 24, 2009
Health Authority: South Korea: Korea Food and Drug Administration (KFDA)

Additional relevant MeSH terms:
Respiratory Tract Infections
Infection
Respiratory Tract Diseases
Telithromycin
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 28, 2014